Skip to main content
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. — Investor Relations & Filings

Ticker · MAZE ISIN · US5787841007 US Manufacturing
Open in API
Filings indexed 139 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country US United States of America
Listing US MAZE

About Maze Therapeutics, Inc.

https://www.mazetx.com/

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that harnesses insights from human genetics to develop novel, small molecule precision medicines. The company utilizes its proprietary Compass platform, which leverages variant functionalization, to identify and validate new therapeutic targets. Maze's strategy focuses on designing medicines that imitate the effects of rare, naturally occurring, protective genetic variants to address common diseases with significant unmet medical needs. Its pipeline is focused on advancing treatments for renal and cardio-metabolic indications, with a lead program targeting APOL1-mediated kidney disease (AMKD).

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 92% confidence The document is a Form 8-K “Current Report” filed under Item 5.02, detailing the resignation of a senior officer (Senior Vice President, Finance) and the designation of a principal accounting officer. This is an announcement of changes to senior management, fitting the Board/Management Information category.
2026-05-22 English
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Regulatory Filings Classification · 84% confidence The document is a Current Report on Form 8-K filed with the SEC, specifically furnishing an earnings press release as Exhibit 99.1 under Item 2.02. It is not the full earnings release itself (which is attached as an exhibit) nor a standalone financial report (e.g., 10-K, IR), but a regulatory filing of Form 8-K. There is no dedicated code for Form 8-K in the taxonomy, so it falls under the general Regulatory Filings category.
2026-05-12 English
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 21, 2026, reporting an underwriting agreement for a new stock offering by Maze Therapeutics, Inc. It details the issuance and sale of common stock and pre-funded warrants, including pricing, use of proceeds, and related legal opinions. The document is focused on a capital raising event and financing activity. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. The content clearly fits the category of a Capital/Financing Update, as it announces a new equity offering and related underwriting agreement. The document length is over 10,000 characters and contains substantive details about the financing transaction, not just an announcement of a report publication or a certification. Therefore, the correct classification is Capital/Financing Update (CAP).
2026-04-22 English
144 - Maze Therapeutics, Inc. (0001842295) (Subject)
Regulatory Filings
2026-03-30 English
10-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Annual Report FY 2025
2026-03-25 English
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes multiple items: Item 2.02 reports financial results for the quarter and year ended December 31, 2025, but it states that the full text of the press release is furnished as an exhibit, indicating this document itself is not the earnings release but a filing of the press release. Item 5.02 announces the appointment of a new director, which is a change in the board of directors. Item 7.01 includes a press release about clinical trial data. The document is primarily an announcement of events and includes no detailed financial statements or substantive financial data itself. The presence of director appointment information and financial results announcement in a Form 8-K suggests the primary classification is Board/Management Information (MANG) because the director appointment is a significant event. The financial results are referenced but not presented in detail, so it is not an Earnings Release (ER). The document is not a report publication announcement (RPA) because it contains substantive information about the director appointment. Therefore, the best classification is MANG with high confidence.
2026-03-25 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.